The history of product label changes for DEFINITY® in the US

US Cardiology

Volumn 9, Issue 1, 2012, Pages 35-39

  Patil, Harshal ^a   Main, Michael L ^a  

^a St Luke's Mid America Heart   (United States)

Author keywords

Contrast enhanced echocardiography; Contrast enhanced ultrasound; Definity ; ultrasound contrast agents; US Food and Drug Administration

Indexed keywords

ECHO CONTRAST MEDIUM; PERFLUTREN;

ADVISORY COMMITTEE; ARTICLE; CONTRAST ECHOCARDIOGRAPHY; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG LABELING; DRUG MONITORING; DRUG PACKAGING; DRUG SAFETY; HUMAN; MICROBUBBLE; PATIENT MONITORING; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; PUBLICATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; UNITED STATES; ECHOCARDIOGRAPHY; FOOD AND DRUG ADMINISTRATION; SCIENTIFIC LITERATURE;

EID: 84866771314     PISSN: 17583896     EISSN: 1758390X     Source Type: Journal    
DOI: 10.15420/usc.2012.9.1.35     Document Type: Article

References (28)

1. US Food and Drug Administration, Initial prescribing information for Definity on July 31, 2001. Available at: www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-064_Definity_prntlbl.pdf (accessed December 18, 2011).
2. Main ML, Goldman JH, Grayburn PA, Thinking outside the 'box' - the ultrasound contrast controversy, J Am Coll Cardiol, 2007;50:2434-7
3. US Food and Drug Administration, Revised prescribing information for Definity on October 10, 2007. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2007/021064s007lbl.pdf (accessed December 18, 2011).
4. Abdelmoneim SS, Bernier M, Scott CG, et al., Safety of contrast agent use during stress echocardiography: a 4-year experience from a single-center cohort study of 26,774 patients, JACC Cardiovasc Imaging, 2009;2:1048-56.
5. Abdelmoneim SS, Bernier M, Scott CG, et al., Safety of contrast agent use during stress echocardiography in patients with elevated right ventricular systolic pressure: a cohort study, Circ Cardiovasc Imaging, 2010;3:240-8.
6. Dolan MS, Gala SS, Dodla S, et al., Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience, J Am Coll Cardiol, 2009;53:32-8.
7. Exuzides A, Main ML, Colby C, et al., A retrospective comparison of mortality in critically ill hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent, JACC Cardiovasc Imaging, 2010;3:578-85.
8. Gabriel RS, Smyth YM, Menon V, et al., Safety of ultrasound contrast agents in stress echocardiography, Am J Cardiol, 2008;102:1269-72.
9. Herzog CA, Incidence of adverse events associated with use of perflutren contrast agents for echocardiography, JAMA, 2008;299:2023-5
10. Khawaja OA, Shaikh KA, Al-Mallah MH, Meta-analysis of adverse cardiovascular events associated with echocardiographic contrast agents, Am J Cardiol, 2010;106:742-7
11. Kusnetzky LL, Khalid A, Khumri TM, et al., Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies, J Am Coll Cardiol, 2008;51:1704-6.
12. Main ML, Ryan AC, Davis TE, et al., Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (multicenter registry results in 4,300,966 consecutive patients), Am J Cardiol, 2008;102:1742-6.
13. Shaikh K, Chang SM, Peterson L, et al., Safety of contrast administration for endocardial enhancement during stress echocardiography compared with noncontrast stress, Am J Cardiol, 2008;102:1444-50.
14. Wei K, Mulvagh SL, Carson L, et al., The safety of Definity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses, J Am Soc Echocardiogr, 2008;11:1202-6.
15. Main ML, Goldman JH, Grayburn PA, Ultrasound contrast agents: balancing safety versus efficacy, Expert Opin Drug Saf, 2009;8:49-56
16. US Food and Drug Administration, Transcript of the May 2, 2011 Joint Meeting of the Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees. Available at: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMee tingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCom mittee/UCM256586.pdf (accessed December 18, 2011).
17. US Food and Drug Administration, FDA Advisory Committee Briefing Document, Cardiovascular and Renal Drugs Advisory Committee June 24, 2008, Safety Considerations in the Development of Ultrasound Contrast Agents. Available at: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4369b1-01.pdf (accessed December 18, 2011).
18. US Food and Drug Administration, Revised prescribing information for Definity on May 12, 2008. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2008/021064s009lbl.pdf (accessed December 18, 2011).
19. US Food and Drug Administration, Revised prescribing information for Definity on October 24, 2011. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2011/021064s011lbl.pdf (accessed December 18, 2011).
20. Lindner JR, Song J, Jayaweera AR, et al., Microvascular rheology of Definity microbubbles after intra-arterial and intravenous administration, J Am Soc Echocardiogr, 2002;15:396-403.
21. Mulvagh SL, Rakowski H, Vannan MA, et al., American Society of Echocardiography Consensus Statement on the Clinical Applications of Ultrasonic Contrast Agents in Echocardiography, J Am Soc Echocardiogr, 2008;21:1179-201; quiz 281.
22. Kurt M, Shaikh KA, Peterson L, et al., Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort, J Am Coll Cardiol, 2009;53:802-10.
23. Szebeni J, Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity, Toxicology, 2005;216:106-21
24. AuntMinnie.com staff writers, U.S. echo contrast agent use dips in Q2, AuntMinnie's Business and Industry Digital Community, August 14, 2008. Available at: www.auntminnie.com/index.aspx?sec=sup&sub=bai&pag=dis&I temID=82115 (accessed December 18, 2011).
25. Dixon BK, FDA gets flak for contrast warning, Intern Med News, 2008;41:5
26. Grayburn PA, Product safety compromises patient safety (an unjustified black box warning on ultrasound contrast agents by the Food and Drug Administration), Am J Cardiol, 2008;101:892-3
27. Keen C, Ultrasound contrast advocates take aim at FDA black box warning, AuntMinnie's Cardiac Imaging Digital Community January 3, 2008. Available at: www.auntminnie.com/index.aspx?sec=sup&sub=car&pag=dis& ItemID=79499 (accessed December 18, 2011).
28. Wood S, FDA facing mounting pressure to rethink echocontrast warning labels, theheart.org, November 28, 2007. Available at: www.theheart.org/article/830665 (accessed December 18, 2011)